Authors: Hisashi Tsurumi Toshiki Yamada Michio Sawada Senji Kasahara Nobuhiro Kanemura Yasushi Kojima Kenji Fukuno Takeshi Hara Masanao Saio Takeshi Takahashi Masami Oyama Keiya Ozawa Tsuyoshi Takami Hisataka Moriwaki
Publish Date: 2003/11/27
Volume: 130, Issue: 2, Pages: 107-113
Abstract
To compare the efficacy and safety of a biweekly CHOP regimen consisting of cyclophosphamide CPA doxorubicin DOX vincristine VCR and prednisolone PSL and those of a biweekly THPCOP regimen containing pirarubicin THP an anthracyclin with less cardiotoxicity than DOXA prospective randomized phase II study with 80 patients 40 receiving CHOP or THPCOP less than 70 years of age with previously untreated aggressive nonHodgkin’s lymphoma NHL The regimens consisted of DOX or THP 50 mg/m2 CPA 750 mg/m2 VCR 14 mg/m2 and PSL 100 mg/body administered for 5 days every 2 weeks for eight cyclesNo significant differences in known prognostic factors were found between the two groups Complete remission rate was 725 725 for CHOP 725 for THPCOP The 5year overall survival rate was 492 437 for CHOP 540 for THPCOP When the patients were divided into groups with favorable or poor prognostic factors according to the International Prognostic Index survival of the former group L/LI was superior to that of the later group HI/H regardless of chemotherapy regimen P0001 Although grade 3 cardiotoxicity occurred in one patient in the CHOP group no fatal toxic reactions occurred in either group The THPCOP produced results equivalent to those of CHOP regarding efficacy and safety in aggressive NHL patients less than 70 years of age
Keywords: